#United States #New York #Investor Rights #Rosen Law Firm #ADMA Biologics

Overview of the Case

In a recent reminder from the Rosen Law Firm, investors in ADMA Biologics, Inc. (NASDAQ: ADMA) have been alerted to potential securities fraud issues surrounding their investments. The firm is urging those who purchased ADMA securities between August 9, 2024, and March 25, 2026, to consider joining a class action lawsuit. Notably, the deadline to become a lead plaintiff in this case is August 10, 2026.

Background on ADMA Biologics

ADMA Biologics is a biopharmaceutical company that specializes in developing and manufacturing human immunoglobulin therapies for various immune deficiencies. As a public entity, ADMA has obligations to provide truthful financial information and disclose relevant internal controls to its shareholders. However, the class action lawsuit claims that throughout the specified Class Period, ADMA failed to meet these obligations.

Allegations Against ADMA

The lawsuit outlines serious allegations against ADMA Biologics, including:
1. Undisclosed Related Party Transactions: The company reportedly engaged in questionable business activities with related parties that were not disclosed to shareholders.
2. Channel Stuffing Practices: ADMA is accused of artificially inflating its revenue figures through channel stuffing, a practice where a company sends more products to distributors than they can sell to customers, thereby inflating short-term revenue.
3. Inadequate Internal Controls: The lawsuit states that the company did not maintain adequate internal controls over financial reporting, causing inaccuracies in their financial statements.
4. Materially False Statements: As a result of the above practices, statements made by the defendants about the company’s business operations and prospects were allegedly misleading.

These misstatements and omissions, when made public, led to significant financial losses for investors as the stock price of ADMA Biologics fell sharply, impacting their investment value.

Next Steps for Investors

Investors who have purchased ADMA securities during the Class Period may be entitled to file as lead plaintiff in the lawsuit. Interested parties are encouraged to act swiftly, as the Rosen Law Firm has specified the lead plaintiff deadline. Joining the lawsuit involves no out-of-pocket expenditures, given its contingency fee arrangement, which allows investors to seek compensation without upfront costs.

To join the action, investors can visit the Rosen Law Firm's dedicated webpage for this case and submit their information. For additional inquiries, investors can call Phillip Kim, Esq. toll-free at 866-767-3653. It’s critical for potential claimants to understand that they are not represented by counsel unless they formally retain one, and they may choose their own legal representation.

Importance of Selecting Qualified Counsel

Rosen Law Firm advises investors to select counsel with proven experience, particularly in securities class actions. The firm has established itself as a significant player in this field, having secured the largest ever securities settlement involving a Chinese company and consistently ranking among the top firms for case settlements. In 2019 alone, Rosen Law Firm recovered over $438 million for its clients, a testament to its effectiveness and dedication to protecting investor rights.

Conclusion

For those who have invested in ADMA Biologics, the upcoming lead plaintiff deadline presents an opportunity to seek justice and potential compensation for perceived market manipulations and losses incurred. The lawsuit underscores the necessity for transparency in financial reporting and the crucial role that investor rights attorneys play in safeguarding these interests. Investors are encouraged to stay informed and proactive as the situation develops.